MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas
Running, not enrolling · Phase 2
Conditions studied: Plexiform Neurofibroma, Neurofibromatosis Type 1 (NF1)
In brief
This study evaluates mirdametinib (PD-0325901) in the treatment of symptomatic inoperable neurofibromatosis type-1 (NF1)-associated plexiform neurofibromas (PNs). All participants will receive mirdametinib (PD-0325901). Eligible participants may continue in a long-term follow-up phase.
Key facts
- Study ID
- NCT03962543
- Run by
- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
- People needed
- 114
- Starts
- 2019-09-29
- Expected to finish
- 2028-12-22
- Last updated by the study team
- 2026-07-10
Who can join
Age: 2 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Alabama at Birmingham/Children's of Alabama — Birmingham, Alabama, United States
- Mayo Clinic Arizona — Phoenix, Arizona, United States
- Arkansas Children's Hospital — Little Rock, Arkansas, United States
- Children's Hospital Los Angeles — Los Angeles, California, United States
- University of California, Los Angeles (UCLA) — Los Angeles, California, United States
- Children's Hospital of Orange County — Orange, California, United States
- University of California - Irvine Health — Orange, California, United States
- Lucile Packard Children's Hospital Stanford — Palo Alto, California, United States
- University of California - Davis — Sacramento, California, United States
- Children's Hospital Colorado — Aurora, Colorado, United States
- Nemours A. I. duPont Hospital for Children — Wilmington, Delaware, United States
- Children's National Hospital — Washington D.C., District of Columbia, United States
- University of Florida Clinical Research Center — Gainesville, Florida, United States
- Nicklaus Children's Hospital — Miami, Florida, United States
- Florida Hospital Cancer Institute — Orlando, Florida, United States
- Arnold Palmer Hospital for Children — Orlando, Florida, United States
- Johns Hopkins All Children's Hospital — St. Petersburg, Florida, United States
- Moffitt — Tampa, Florida, United States
- University of Illinois Hospital and Health Systems — Chicago, Illinois, United States
- Indiana University — Indianapolis, Indiana, United States
- University of Iowa Health Care — Iowa City, Iowa, United States
- University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan, United States
- Henry Ford Hospital — Detroit, Michigan, United States
- University of Minnesota/Masonic Cancer Center — Minneapolis, Minnesota, United States
- Mayo Clinic — Rochester, Minnesota, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.